ImmunoGen, Inc.

BMV:IMGN * Stock Report

Market Cap: Mex$142.8b

ImmunoGen Management

Management criteria checks 2/4

ImmunoGen's CEO is Mark Enyedy, appointed in May 2016, has a tenure of 7.75 years. total yearly compensation is $5.42M, comprised of 14% salary and 86% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth MX$311.75M. The average tenure of the management team and the board of directors is 1.3 years and 12.1 years respectively.

Key information

Mark Enyedy

Chief executive officer

US$5.4m

Total compensation

CEO salary percentage14.0%
CEO tenure7.8yrs
CEO ownership0.2%
Management average tenure1.3yrs
Board average tenure12.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mark Enyedy's remuneration changed compared to ImmunoGen's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$74m

Jun 30 2023n/an/a

-US$180m

Mar 31 2023n/an/a

-US$240m

Dec 31 2022US$5mUS$759k

-US$223m

Sep 30 2022n/an/a

-US$201m

Jun 30 2022n/an/a

-US$161m

Mar 31 2022n/an/a

-US$129m

Dec 31 2021US$7mUS$735k

-US$139m

Sep 30 2021n/an/a

-US$71m

Jun 30 2021n/an/a

-US$56m

Mar 31 2021n/an/a

-US$49m

Dec 31 2020US$5mUS$714k

-US$44m

Sep 30 2020n/an/a

-US$71m

Jun 30 2020n/an/a

-US$70m

Mar 31 2020n/an/a

-US$89m

Dec 31 2019US$4mUS$710k

-US$104m

Sep 30 2019n/an/a

-US$151m

Jun 30 2019n/an/a

-US$176m

Mar 31 2019n/an/a

-US$174m

Dec 31 2018US$9mUS$687k

-US$169m

Sep 30 2018n/an/a

-US$140m

Jun 30 2018n/an/a

-US$150m

Mar 31 2018n/an/a

-US$117m

Dec 31 2017US$3mUS$670k

-US$96m

Compensation vs Market: Mark's total compensation ($USD5.42M) is above average for companies of similar size in the MX market ($USD2.69M).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.

CEO

Mark Enyedy (59 yo)

7.8yrs

Tenure

US$5,422,421

Compensation

Mr. Mark Joseph Enyedy serves as Independent Director of BioMarin Pharmaceutical Inc. since December 27, 2023. He is Non-Executive Director at Ergomed plc since June 10, 2021. He has been the Chief Executi...

Leadership Team

NamePositionTenureCompensationOwnership
Mark Enyedy
President7.8yrsUS$5.42m0.22%
MX$ 311.7m
Stacy Coen
Senior VP & Chief Business Officer3.7yrsUS$1.84m0.027%
MX$ 39.1m
Michael Vasconcelles
Chief Medical Officer1.2yrsUS$3.81m0.00050%
MX$ 713.9k
Lauren White
Senior VP & Chief Financial Officerless than a yearno datano data
Anabel Chan
Head of Investor Relationsno datano datano data
Daniel Char
Senior VP1.3yrsno data0.00037%
MX$ 528.3k
Courtney O'Konek
Senior Director of Corporate Communications & Investor Relationsno datano datano data
Audrey Bergan
Senior VP & Chief HR Officer5.6yrsno datano data
Theresa Wingrove
Senior Vice President of Regulatory Affairs & Qualityno dataUS$1.27m0.0079%
MX$ 11.2m
Isabel Kalofonos
Senior VP & Chief Commercial Officerless than a yearno datano data

1.3yrs

Average Tenure

59.5yo

Average Age

Experienced Management: IMGN *'s management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Mark Enyedy
President7.8yrsUS$5.42m0.22%
MX$ 311.7m
Stephen McCluski
Independent Chairman16.8yrsUS$257.80k0%
MX$ 0
Dean Mitchell
Independent Director12.1yrsUS$217.80k0.038%
MX$ 54.9m
Kristine Peterson
Independent Director12.1yrsUS$227.80k0%
MX$ 0
Helen Thackray
Independent Director2.4yrsUS$175.00k0.0011%
MX$ 1.6m
Richard Wallace
Independent Director16.3yrsUS$220.30k0.0037%
MX$ 5.3m
Stuart Arbuckle
Independent Director6.1yrsUS$210.30k0.0020%
MX$ 2.9m
Mark A. Goldberg
Independent Director12.3yrsUS$225.30k0.023%
MX$ 32.4m
Tracey McCain
Independent Director2.3yrsUS$146.65k0%
MX$ 0

12.1yrs

Average Tenure

64yo

Average Age

Experienced Board: IMGN *'s board of directors are seasoned and experienced ( 12.1 years average tenure).